



Cardiac glycosides from *Cryptostegia grandiflora*

M.S. Kamel^{a,*}, M.H. Assaf^a, Y. Abe^b, K. Ohtani^b, R. Kasai^b, K. Yamasaki^b

^aDepartment of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt

^bInstitute of Pharmaceutical Sciences, Hiroshima University, Faculty of Medicine, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734, Japan

Received 1 May 2001; received in revised form 25 June 2001

Abstract

From the leaves of *Cryptostegia grandiflora*, four new cardiac glycosides oleandrigenin 3-*O*- β -glucopyranosyl-(1 \rightarrow 4)- β -cymaropyranosyl-(1 \rightarrow 4)- β -digitoxopyranoside, cryptostigmin I, oleandrigenin 3-*O*- β -glucopyranosyl-(1 \rightarrow 4)- α -rhamnopyranoside, cryptostigmin II, 16-propionylgitoxigenin 3-*O*- β -glucopyranosyl-(1 \rightarrow 4)- α -rhamnopyranoside, cryptostigmin III and oleandrigenin 3-*O*- β -glucopyranosyl-(1 \rightarrow 6)- β -glucopyranosyl-(1 \rightarrow 4)- β -cymaropyranosyl-(1 \rightarrow 4)- β -digitoxopyranoside, cryptostigmin IV have been isolated together with two known cardenolides subalpinosid and 16-*O*-acetyl-digitalinum verum. The structures of the isolated compounds were verified by means of MS and NMR spectral analyses. © 2001 Elsevier Science Ltd. All rights reserved.

Keywords: *Cryptostegia grandiflora*; Asclepiadaceae; Cardenolides; Cryptostigmin I–IV

1. Introduction

Cryptostegia grandiflora R.Br. (Asclepiadaceae) is an ornamental plant commonly cultivated in Egypt and warm countries (Metcalf and Chalk, 1950; Chopra et al., 1965; Hutchinson, 1973). The plant has a wide use in manufacturing of rubber and as a source of hydrocarbon fuels from its latex (Mehta et al., 1982). Three cardiac glycosides were isolated from *Cryptostegia madagascarensis* (14, 16-dianhydrogitoxigenin-3-rhamnoside, 16-propionylgitoxigenin-3-rhamnoside and 16-anhydrogitoxigenin-3-rhamnoside) (Sanduja et al., 1984) while few cardenolides (cryptograndoside A, B and digitalinum verum) have been already isolated and identified from *C. grandiflora* (Watt and Breyer, 1962). Moreover, the macro and micromorphological characters of the leaves and stems of *C. grandiflora* have been also investigated (Assaf, 1998). The present study deals with the isolation and structure elucidation of four new cardiac glycosides together with two known glycosides from the leaves of *C. grandiflora*.

2. Results and discussion

The ethanolic extract of the leaves of *C. grandiflora* was defatted with CH₂Cl₂ and the aqueous layer was subjected to a column chromatography of Diaion HP-20. The 80% methanol eluate was repeatedly chromatographed on columns of silica gel and then by MPLC and HPLC to afford 6 glycosides.

Comparison of the NMR spectra of compound **1** with the published data revealed its structure as subalpinosid previously isolated from *Digitalis subalpina* (Lichius et al., 1991).

The molecular formula of compound **2** was deduced as C₄₄H₆₈O₁₇ from HR FAB–MS spectrometry (see Experimental section). The ¹³C NMR spectrum (Tables 1 and 2) of **2** displayed the presence of one unsubstituted β -glucopyranosyl unit from the signals at δ_c 104.3 (C-1), 74.9 (C-2), 78.2 (C-3 and 5), 71.9 (C-4) and 63.0 (C-6), one substituted β -digitoxopyranosyl unit from the signals at δ_c 96.5 (C-1), 38.9 (C-2), 71.8 (C-3), 83.0 (C-4), 67.5 (C-5) and 18.6 (C-6) and one substituted β -cymaropyranosyl unit from the signals at δ_c 101.3 (C-1), 37.2 (C-2), 78.5 (C-3), 83.4 (C-4), 68.5 (C-5), 18.7 (C-6) and 56.7 (OMe) (Bradbury and Jenkins, 1984) together with 25 carbon signals for the aglycone. The chemical shifts of the aglycone carbons were similar to those reported for 3-*O* substituted oleandrigenin (Lichius et al., 1991). The downfield shifts of C-4 of the digitoxo- and

* Corresponding author. Tel.: +20-88-333196; fax: +20-88-332776.

E-mail address: mkamel@mailcity.com (M.S. Kamel).

Table 1
¹³C NMR spectral data of the aglycone moieties of compounds **2–5** (100 MHz, C₅D₅N)^a

C	2	3	4	5
1	30.4	30.1	30.1	30.4
2	26.9	26.9	27.0	27.0
3	73.2	72.6	72.8	73.2
4	30.7	30.9	30.9	30.8
5	36.9	36.9	37.0	36.9
6	26.9	26.7	26.8	27.0
7	21.1 ^a	21.1 ^a	21.1 ^a	21.1 ^a
8	41.8	41.8	41.9	41.9
9	35.7	35.6	35.7	35.8
10	35.4	35.3	35.4	35.4
11	21.6 ^a	21.6 ^a	21.6 ^a	21.6 ^a
12	39.1	38.9	38.9	39.1
13	50.4	50.4	50.4	50.4
14	83.6	83.3	83.3	83.4
15	41.1	41.1	41.3	41.1
16	75.6	76.3	76.4	75.4
17	75.3	56.7	56.8	57.6
18	16.2	16.2	16.2	16.2
19	23.8	23.9	23.9	23.9
20	169.8	169.9	169.8	169.8
21	76.2	76.2	76.3	76.2
22	121.5	121.5	121.6	121.5
23	174.2	174.2	174.2	174.2
-COMe	170.2	170.3	173.7	170.2
-COMe	20.7	20.6		20.7
-COCH ₂ Me			9.1	
-COCH ₂ Me			27.7	

^a a, b values may be interchangeable in each column.

cymaropyranosyl units (δ_c 83.0 and 83.4 respectively) proved their substitution at C-4 of each unit (Bradbury and Jenkins, 1984). In the ¹H NMR spectrum of **2**, the doublet signal at δ_H 5.04 (1H) with *J* (constant) 7.8 Hz for the anomeric proton of the glucosyl residue indicated the β configuration. Moreover, the broad doublet signal at δ_H 5.39 (*J* constant 9.1 Hz) and the doublet of doublet signal at δ_H 4.71 (*J* constant 4.7 and 9.5 Hz) indicated the β configuration of the digitoxo- and cymaropyranosyl units respectively. The HMQC spectral data of **2** revealed the correlations between each carbon and its directly attached protons while H–H COSY interpreted the proton–proton couplings. The HMBC spectral analysis of **2** (Fig. 1) displayed significant correlation peaks between H-1 of the digitoxopyranosyl unit with C-3 of the aglycone as well as H-16 with COMe and H-22 with C-23. The negative FAB–MS spectrum of **2** exhibited M⁺ at *m/z* 867 [M–H][–] as well as a significant peak at *m/z* 705 [M–H–glucose][–] and a peak at *m/z* 561 [M–H–(glucose + cymarose)][–]. Therefore, the internal sugar unit was confirmed as the digitoxopyranosyl unit and the structure of compound **2** was assigned as oleandrigenin 3-*O*- β -glucopyranosyl-(1→4)- β -cymaropyranosyl-(1→4)- β -digitoxopyranoside and named cryptostigmin I.


Table 2
¹³C NMR spectral data of the sugar moieties of compounds **2–5** (100 MHz, C₅D₅N)^a

C ^b	2	3	4	5
<i>Dig</i>				
1	96.5			96.5
2	38.9			38.9
3	71.8			71.7
4	83.0			83.0
5	67.5			67.5
6	18.6			18.6
<i>Cym</i>				
1	101.3			101.4
2	37.2			37.4
3	78.5			78.5
4	83.4			83.7
5	68.5			68.5
6	18.7			18.7
<i>OMe</i>				
	56.7			56.8
<i>Rha</i>				
1		99.6	99.6	
2		71.4	71.4	
3		72.2	72.3	
4		85.1	85.2	
5		68.3	68.3	
6		18.4	18.4	
<i>Glc</i>				
	104.3	106.6	107.7	104.3
1	74.9	74.9	74.7	74.9
2	78.2	78.3 ^a	78.4 ^a	78.3 ^b
3	71.9	72.4	72.5	72.1
4	78.2	78.4 ^a	78.5 ^a	77.4
5	63.0	62.5	62.6	70.2
6				
<i>Glc</i>				
1				105.1
2				74.9
3				78.2 ^b
4				72.1
5				78.3 ^b
6				62.8

^a a, b: values may be interchangeable in each column.

^b Dig: β -Digitoxopyranose, Cym: β -Cymaropyranose, Rha: α -Rhamnopyranose, Glc: β -Glucopyranose.

The molecular formula of compound **3** was deduced as C₃₇H₅₆O₁₅ from HR FAB–MS spectrometry (see Experimental section). ¹³C NMR spectral data of **3** (Tables 1 and 2) were very similar to those of **2** in the aglycone moiety indicating the presence of 3-*O* substituted oleandrigenin as aglycone. The signals of the sugar moiety revealed the presence of a terminal β -glucopyranosyl unit in addition to α -substituted a rhamnopyranosyl unit from the signals at δ_c 99.6 (C-1), 71.4 (C-2), 72.2 (C-3), 85.1 (C-4), 68.3 (C-5) and 18.4 (C-6) (Breitmaier and Voelter, 1987). The downfield shift of C-4 of the rhamnopyranosyl unit (δ_c 85.1) indicated its substitution at this position. The β configuration of the glucopyranosyl unit was deduced from the doublet signal of its anomeric proton at δ_H 5.20 with *J* constant 7.7



	R ₁	R ₂
(2)	– Dig — ⁴ — Cym — ⁴ — Glc	–CH ₃
(3)	– Rha — ⁴ — Glc	–CH ₃
(4)	– Rha — ⁴ — Glc	–CH ₂ –CH ₃
(5)	– Dig — ⁴ — Cym — ⁴ — Glc — ⁶ — Glc'	–CH ₃

Dig: β-digitoxopyranose, **Cym:** β-cymaropyranose, **Rha:** α-rhamnopyranose, **Glc:** β-glucopyranose

Hz in the ¹H NMR spectrum while the configuration of the rhamnopyranosyl unit was established from the upfield shift of its C-5 (δ_c 68.3) in the ¹³C NMR spectrum (Kasai et al., 1979). The structural assignment was confirmed by carrying out 2D NMR techniques such as HMQC and H–H COSY. The HMBC spectral analysis of **3** (Fig. 1) displayed correlation peaks between H-3 and C-1 of the rhamnopyranosyl unit, the anomeric proton of the glucosyl residue and C-4 of the rhamnosyl unit, H-16 and both COMe and C-20, H-17 and COMe, H-21, 21' with C-23 and H-22 with C-23. The negative FAB–MS spectrum of **3** showed significant peaks at *m/z* 739 [M–H][–] and 577 [M–H–glucose][–] confirming the sequence of the sugar moiety. Consequently, the structure of **3** was determined as oleandrigenin 3-*O*-β-glucopyranosyl-(1→4)-α-rhamnopyranoside and named cryptostigmin II.

The molecular formula of compound **4** was established as C₃₈H₅₈O₁₅ from HR FAB–MS spectrometry (see Experimental section). Inspection of ¹³C NMR spectral data of **4** (Tables 1 and 2) revealed their similarity to those of **3** both in the aglycone and sugar moieties. However, the presence of a methylene signal at δ_c 27.7 and a methyl signal at δ_c 9.1 in addition to the absence of the methyl signal at δ_c 20.6 in compound **4** proved the presence of a propionyl instead of the acetyl moiety at C-16 of the aglycone. At the same time, ¹H

NMR spectrum of compound **4** showed a quartet at δ_H 2.13 (*J* constant 7.3 Hz) and a triplet at δ_H 0.93 (*J* constant 7.6 Hz) for the methylene and methyl groups of the propionyl moiety, respectively, in addition to the absence of the methyl singlet at δ_H 1.82 of the acetyl group when compared with compound **3**. Moreover, FAB–MS spectrum of **4** exhibited significant peaks at *m/z* 753 [M–H][–], 591 [M–H–glucose][–] and 445 [M–H–(glucose + rhamnose)][–]. Consequently, the structure of compound **4** was assigned as 16-propionylgitoxigenin 3-*O*-β-glucopyranosyl-(1→4)-α-rhamnopyranoside and named cryptostigmin III.

The molecular formula of compound **5** was determined as C₅₀H₇₈O₂₂ from HR FAB–MS spectrometry (see Experimental section). Inspection of ¹³C NMR spectral data of **5** (Tables 1 and 2) revealed their similarity to those of **2** both in the aglycone and sugar moieties. However, the downfield shift of C-6 of the glucosyl unit to δ_c 70.2 (+ 7.2 ppm) revealed its substitution at this position with an additional glucopyranosyl unit from the signals at δ_c 105.1, 74.9, 78.2, 72.1, 78.3 and 62.8 (Bradbury and Jenkins, 1984). In the ¹H NMR spectrum of **5**, the doublet signals at δ_H 5.19 and 4.99 (each 1H) with *J* constant 7.8 Hz for each one of the anomeric protons of the glucosyl residues indicated the β configuration. Moreover, the broad doublet signal at




Fig. 1. Significant HMBC correlations of compounds 2 and 3.

δ_{H} 4.79 (J constant 11.7 Hz) and the doublet of doublet signal at δ_{H} 4.73 (J constant 3.9 and 7.2 Hz) indicated the β configuration of the digitoxo- and cymaropyranosyl units respectively. FAB-MS spectrum of **5** exhibited significant peaks at m/z 1029 $[\text{M}-\text{H}]^-$, 867 $[\text{M}-\text{H}-\text{glucose}]^-$, 705 $[\text{M}-\text{H}-(2 \text{ glucose})]^-$ and 561 $[\text{M}-\text{H}-(2 \text{ glucose} + \text{cymarose})]^-$. Consequently, the structure of compound **5** was assigned as oleandrigenin 3- O - β -glucopyranosyl-(1 \rightarrow 6)- β -glucopyranosyl-(1 \rightarrow 4)- β -cymaropyranosyl-(1 \rightarrow 4)- β -digitoxopyranoside and named cryptostigmin IV.

Comparison of the ^1H and ^{13}C NMR spectra of compound **6** with the published data deduced its structure as 16- O -acetyl-digitalinum verum previously isolated from *Addenium obesum* (Yamauchi and Abe, 1990).

3. Experimental

^1H and ^{13}C NMR (TMS as int. standard): 400 and 100 MHz, respectively were recorded on a JEOL JNM α -400

spectrometer. FAB-MS spectra were taken on a JEOL JMS-SX 102 spectrometer by direct inlet method at an ionizing voltage of 70 eV. Optical rotations were measured with a Union PM-I digital polarimeter. MPLC: RP-18 column (20 mm i.d. \times 40 cm); flow rate of mobile phase 3 ml/min. HPLC: D-ODS-5 and polyamine columns (each 20 mm i.d. \times 25 cm, YMC) with a Toyo Soda high speed chromatograph HLC-803 D pump and a Tosoh refraction index (R1-8) detector; flow rate of mobile phase 6 ml/min, injection vol. 0.8–1.0 ml. On the ODS column, 30% MeCN (I) and 25% MeCN (II) were used while 90% MeCN (III) and 85% MeCN (IV) were used on the polyamine column. CC: Kieselgel 60 (70–230 mesh, Merck) and Diaion HP 20 (Mitsubishi). TLC: silica gel 60 pre-coated plates F-254 and HPTLC using RP-18 pre-coated plates, F-254 s (Merck).

3.1. Plant material

Leaves of *C. grandiflora* R.Br. (Asclepiadaceae) were collected from the trees cultivated in the Experimental

Station of Faculty of Agriculture, Assiut University, Assiut, Egypt, in March 1997. The plant was identified by Professor N. El-Keltawi, Department of Horticulture, Faculty of Agriculture, Assiut University, Assiut, Egypt. A voucher specimen is deposited at the Herbarium of Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, Egypt.

3.2. Extraction and isolation of compounds (1–6)

The air-dried powdered leaves of *C. grandiflora* (2 kg) were extracted with 70% EtOH. The dried ethanolic extract (499 g) was suspended in H₂O and defatted successively with *n*-hexane and CH₂Cl₂. The aq. fr. was applied to a column of Diaion HP-20 and eluted with H₂O, 40% MeOH, 80% MeOH, MeOH and acetone successively. The 80% MeOH eluate (12 g) was chromatographed by silica gel CC using CH₂Cl₂–MeOH–H₂O (85: 15: 1) and finally with (70 : 30 : 3) to give 4 fractions. Fraction 1 (760 mg) was separated by MPLC on RP-18 using 35% MeCN and HPLC using ODS column and solvent I to afford compounds **1** (white powder, 14 mg) and **6** (white powder, 53 mg). Fraction 2 (718 mg) was subjected to HPLC using polyamine column and solvent III to give compound **2** (white powder, 70 mg). Fraction 3 (610 mg) was separated by HPLC using polyamine column and solvent IV to afford compounds **3** (white powder, 149 mg) and **4** (white powder, 43 mg). Fraction 4 (2.5 g) was separated by MPLC on RP-18 using 30% MeCN as a solvent system and HPLC using ODS column and solvent II to afford compound **5** (white powder, 29 mg).

3.2.1. Compound (2)

Cryptostigmin I, $[\alpha]_D^{25}$ –15.4° (MeOH; *c* 5.70). HR FAB–MS (negative) *m/z*: 867.4371 [M–H][–] C₄₄H₆₈O₁₇ (req. 867.4378). ¹³C NMR (C₅D₅N, Tables 1 and 2). ¹H NMR (C₅D₅N): δ_H 6.30 (1H, *s*, H-22), 5.63 (1H, *m*, H-16), 5.40 (1H, *d*, *J* = 18.1 Hz, H-21), 5.39 (1H, *bd*, *J* = 9.1 Hz, H-1 Dig), 5.20 (1H, *d*, *J* = 18.1 Hz, H-21'), 5.04 (1H, *d*, *J* = 7.8 Hz, H-1 Glc), 4.71 (1H, *dd*, *J* = 4.7 and 9.5 Hz, H-1 Cym), 3.49 (3H, *s*, OMe), 3.35 (1H, *d*, *J* = 8.8 Hz, H-17), 2.77 (1H, *dd*, *J* = 8.6 and 14.6 Hz, H-15), 2.02 (1H, *d*, *J* = 13.2 Hz, H-15'), 1.82 (3H, *s*, COMe), 1.58 (3H, *d*, *J* = 5.4 Hz, Me-6 Cym), 1.42 (3H, *d*, *J* = 6.1 Hz, Me-6 Dig), 1.04 (3H, *s*, Me-18) and 0.84 (3H, *s*, Me-19).

3.2.2. Compound (3)

Cryptostigmin II, $[\alpha]_D^{25}$ –39.4° (MeOH; *c* 3.73). HR FAB–MS (negative) *m/z*: 739.3604 [M–H][–] C₃₇H₅₆O₁₅ (req. 739.3541). ¹³C NMR (C₅D₅N, Tables 1 and 2). ¹H NMR (C₅D₅N): δ_H 6.32 (1H, *bs*, H-22), 5.66 (1H, *m*, H-16), 5.40 (1H, *dd*, *J* = 1.8, 18.3 Hz, H-21), 5.32 (1H, *bs*, H-1 Rha), 5.22 (1H, *dd*, *J* = 1.5, 18.3 Hz, H-21'), 5.20

(1H, *d*, *J* = 7.7 Hz, H-1 Glc), 4.18 (1H, *m*, H-3), 3.37 (1H, *d*, *J* = 8.6 Hz, H-17), 2.78 (1H, *dd*, *J* = 9.5 and 15.7 Hz, H-15), 2.03 (1H, *dd*, *J* = 2.1, 15.3 Hz, H-15'), 1.82 (3H, *s*, COMe), 1.67 (3H, *d*, *J* = 6.4 Hz, Me-6 Rha), 1.05 (3H, *s*, Me-18) and 0.81 (3H, *s*, Me-19).

3.2.3. Compound (4)

Cryptostigmin III, $[\alpha]_D^{25}$ –41.3° (MeOH; *c* 2.01). HR FAB–MS (negative) *m/z*: 753.3683 [M–H][–] C₃₈H₅₈O₁₅ (req. 753.3697). ¹³C NMR (C₅D₅N, Tables 1 and 2). ¹H NMR (C₅D₅N): δ_H 6.32 (1H, *bs*, H-22), 5.70 (1H, *m*, H-16), 5.41 (1H, *d*, *J* = 18.3 Hz, H-21), 5.22 (1H, *d*, *J* = 18.3 Hz, H-21'), 5.20 (1H, *d*, *J* = 7.1 Hz, H-1 Glc), 3.40 (1H, *d*, *J* = 8.8 Hz, H-17), 2.80 (1H, *d*, *J* = 14.8 Hz, H-15), 2.13 (2H, *q*, *J* = 7.3 Hz, COCH₂), 2.10 (1H, *d*, *J* = 14.8 Hz, H-15'), 1.68 (3H, *d*, *J* = 6.1 Hz, Me-6 Rha), 1.07 (3H, *s*, Me-18), 0.93 (3H, *t*, *J* = 7.6 Hz, CO–CH₂–Me) and 0.83 (3H, *s*, Me-19).

3.2.4. Compound (5)

Cryptostigmin IV, $[\alpha]_D^{25}$ –37.8° (MeOH; *c* 1.80). HR FAB–MS (negative) *m/z*: 1029.4891 [M–H][–] C₅₀H₇₈O₂₂ (req. 1029.4906). ¹³C NMR (C₅D₅N, Tables 1 and 2). ¹H NMR (C₅D₅N): δ_H 6.32 (1H, *s*, H-22), 5.40 (1H, *d*, *J* = 18.6 Hz, H-21), 5.22 (1H, *d*, *J* = 18.6 Hz, H-21'), 5.19 and 4.99 (each 1H, *d*, *J* = 7.8 Hz, H-1 Glc and Glc'), 4.79 (1H, *bd*, *J* = 11.7 Hz, H-1 Dig), 4.73 (1H, *dd*, *J* = 3.9 and 7.2 Hz, H-1 Cym), 3.60 (3H, *s*, OMe), 3.36 (1H, *d*, *J* = 9.1 Hz, H-17), 2.78 (1H, *dd*, *J* = 10.0 and 15.2 Hz, H-15), 2.04 (1H, *d*, *J* = 15.2 Hz, H-15'), 1.83 (3H, *s*, COMe), 1.57 (3H, *d*, *J* = 6.1 Hz, Me-6 Cym), 1.43 (3H, *d*, *J* = 6.4 Hz, Me-6 Dig), 1.05 (3H, *s*, Me-18) and 0.85 (3H, *s*, Me-19).

Acknowledgements

The authors are grateful to the Japan Society for Promotion of Science (JSPS) and a Grant-in-Aid, Ministry of Education and Culture, Japan for the financial support of this work. Also, we would like to thank the Research Center of Molecular Medicine of the Hiroshima University School of Medicine, Japan, for NMR measurements.

References

- Assaf, M., 1998. Macro- and micromorphological study of the leaves and stems of *Cryptostegia grandiflora* R.Br. cultivated in Egypt. Bulletin of Pharmaceutical Sciences. Assiut University 21, 61–74.
- Bradbury, H., Jenkins, J., 1984. Determination of the structures of trisaccharides by ¹³C NMR spectroscopy. Carbohydr. Res. 126, 125–156.
- Breitmaier, E., Voelter, W., 1987. Carbon-13 NMR Spectroscopy, 3rd Edition. Verlagsgesellschaft mbH, Weinheim, Germany. pp. 381–382.

- Chopra, R., Badhwar, R., Ghosh, S., 1965. Poisonous Plants of India, Vol. I. Indian council of Agricultural Research, pp. 577–578.
- Hutchinson, J., 1973. The families of flowering plants, 3rd Edition. The Clarendon Press, Oxford, p. 472.
- Kasai, R., Okihara, M., Asakawa, J., Mizutani, K., Tanaka, O., 1979. ^{13}C NMR study of α - and β -anomeric pairs of D-mannopyranosides and L-rhamnopyranosides. Tetrahedron 35, 1427–1432.
- Lichius, J., El Khyari, D., Wichtl, M., 1991. Subalpinosid (S1) a new oleandrogenin glycoside and other cardenolides from *Digitalis subalpina* var. *subalpina*. Planta Med. 57, 159–161.
- Mehta, H., Doshi, A., Choudhari, P., Bokil, K., Rao, S., 1982. Liquid fuels from laticiferous plants. Ind. J. Technol. 20, 454–456.
- Metcalf, C., Chalk, L., 1950. Anatomy of the dicotyledons, Vol II. The Clarendon Press, Oxford, p. 914.
- Sanduja, R., Lo, W., Euler, K., Alam, M., 1984. Cardenolides of *Cryptostegia madagascarensis*. J. Nat. Prod. 47, 260–265.
- Watt, J., Breyer, M., 1962. Medicinal and poisonous plants of southern and eastern Africa. Livingstone, London. p. 69.
- Yamauchi, T., Abe, F., 1990. Cardiac glycosides and pregnanes from *Addenium obesum*. Chem. Pharm. Bull. 38, 669.